IP Library Patent Application 13515399
Patent Application
App. No. 13/515,399

FORMULATIONS AND METHODS FOR CONTROLLING MDI PARTICLE SIZE DELIVERY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/515,399
Abstract

Provided herein are formulations, methods, and metered dose inhaler drug delivery devices. The formulations and methods may provide for controlled particle size delivery in metered dose inhaler drug delivery devices. Further provided are metered dose inhaler drug delivery devices that may themselves deliver controlled sized particles to the airways.

Claims (29)

1 . A metered dose inhaler containing an aerosol formulation comprising:

propellant;

at least one drug dissolved in the formulation;

at least one other drug in undissolved particulate form suspended in the formulation and having a mass median diameter of less than 1.7 microns.

2 . A method of increasing the codeposition characteristics of two or more drugs delivered from a metered dose inhaler aerosol, comprising:

providing in a propellant formulation having at least one drug dissolved in the formulation, and at least one drug as a particulate suspended in the formulation having a mass median diameter of less than 1.7 microns.

3 . The metered dose inhaler of claim 1 , wherein the at least one drug dissolved in the formulation is selected from the group consisting of beclomethasone dipropionate, ciclesonide, flunisolide, budesonide, fluticasone propionate, ipratropium, and tiotropium, mometasone, formoterol, including any physiologically acceptable salt, solvate, or enantiomer of any of the foregoing.

4 . The metered dose inhaler of claim 1 , where the drug dissolved in the formulation is present at a concentration of at least 0.01% by weight of the formulation.

5 . The metered dose inhaler of claim 1 , wherein the propellant includes a compound selected from the group consisting of 1,1,1,2-tetrafluoroethane (HFC-134a), 1,1,1,2,3,3,3-heptafluoropropane (HFC-227), and mixtures thereof.

6 . The metered dose inhaler of claim 1 , wherein the at least one other drug in undissolved particulate form suspended in the formulation is selected from the group consisting of albuterol, formoterol, and salmeterol, including any physiologically acceptable salt, solvate, or enantiomer of any of the foregoing.

7 . The metered dose inhaler of claim 1 , wherein the at least one other drug in undissolved particulate form suspended in the formulation has a mass median diameter of no greater than 1.4 microns.

8 . The metered dose inhaler or method of claim 6 , wherein the mass median diameter is no greater than 1 micron.

9 . The metered dose inhaler of claim 1 , further comprising ethanol.

10 . The metered dose inhaler of claim 1 , further comprising a dispersing aid.

11 . The metered dose inhaler of claim 1 , wherein the number of suspended drug particles is at least 3×10 9 suspended particles per milliliter of formulation.

12 . The metered dose inhaler of claim 1 , wherein the number of suspended drug particles is at least 1×10 10 suspended particles per milliliter of formulation.

13 . The metered dose inhaler of claim 1 , further comprising a particulate bulking agent.

14 . A metered dose inhaler containing an aerosol formulation comprising:

propellant;

one or more drugs all of which is in dissolved form;

at least one non-drug bulking agent in undissolved particulate form suspended in the formulation.

15 . The metered dose inhaler of claim 14 , wherein the drug is selected from the group consisting of beclomethasone dipropionate, fluticasone propionate, budesonide, mometasone, ciclesonide, flunisolide, ipratropium, and tiotropium, including any physiologically acceptable salt, solvate, or enantiomer of any of the foregoing.

16 . The metered dose inhaler of claim 14 , where the drug dissolved in the formulation is present at a concentration of at least 0.01% by weight of the formulation.

17 . The metered dose inhaler of claim 14 , wherein the propellant includes a compound selected from the group consisting of 1,1,1,2-tetrafluoroethane (HFC-134a), 1,1,1,2,3,3,3-heptafluoropropane (HFC-227), and mixtures thereof.

18 . The metered dose inhaler of claim 14 , wherein the bulking agent is selected from the group consisting of lactose, DL-alanine, ascorbic acid, glucose, sucrose, D(+)trehalose.

19 . The metered dose inhaler of claim 14 , further comprising ethanol.

20 . The metered dose inhaler of claim 14 , further comprising a dispersing aid.

21 . The metered dose inhaler of claim 14 , wherein the non-drug bulking agent has a mass median diameter of at least 2 microns.

22 . The metered dose inhaler of claim 1 , further comprising a dissolved low-volatility excipient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2012
From: STEIN, STEPHEN W.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 028360/0223 →